Company intelligence / Profile preview

Accunea

London/Kidderminster, England, United Kingdomaccunea.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Accunea’s RenoSure device provides real-time, continuous bioanalysis of kidney function using established biomarkers such as creatinine. The technology aims to reduce the number of discarded donor kidneys by providing dynamic molecular insights pre-, peri-, and post-transplantation. Early clinical results suggest improved decision-making for organ viability and patient recovery through sensitive detection of metabolic changes. The company collaborates with leading UK academic centers for ongoing validation.

Therapeutic areas: Nephrology
Modalities: DeviceAI-enabled diagnostics (point-of-care biosensor device)
Industry: Physiological Monitoring

Partnerships

Collaborations with leading UK academic institutions and transplant centers for clinical studies/validation

Beyond the preview

Go deeper on Accunea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accunea.

Explore the full profile